Sort
10,766 grants matching “checkpoint inhibitor”
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
$477,643Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$477,498Anjana Rao · La Jolla Institute For Immunology · R01 · FY2024 · CA
In chronic myeloid leukemia, persistence of leukemia stem cells during tyrosine kinase inhibitor treatment is influenced by interaction with αβT cells
$477,218Elizabeth Ann Eklund · Northwestern University At Chicago · R01 · FY2025 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$477,136Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
PKCdelta and salivary gland radioprotection
$477,065Mary Elaine Reyland · University Of Colorado Denver · R01 · FY2022 · DE
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$476,998Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance
$476,960Willy Hugo · University Of California Los Angeles · R01 · FY2020 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$476,752Wei R. Chen · University Of Oklahoma · R01 · FY2023 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
$476,736Xinna Zhang · Indiana University Indianapolis · R01 · FY2024 · CA
Developing newly combined therapeutic strategies for mature B cell lymphoma
$476,638Jing Hong Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$476,622Elias Sayour · University Of Florida · R37 · FY2022 · CA
Exploiting oxidative stress response in uveal melanoma liver metastases
$476,587Edward Hartsough · Drexel University · R01 · FY2024 · CA
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
$476,442Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2021 · CA
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
$476,037Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Mechanisms of Nucleic Acid Enzymes - Pol Beta, HIV-1 Reverse Transcriptase and Mammalian Base Repair Enzymes
$475,975Samuel H Wilson · National Institute Of Environmental Health Sciences · ZIA · FY2022 · ES
Duke-UNC Chapel Hill Immunotherapy Training Grant
$475,705Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2019 · CA
Project 1: Delta immune Ecology of NSCLC
$475,697Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2024 · CA
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
$475,682Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
$475,682Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Investigating the roles of extracellular cGAMP and harnessing it for cancer treatment
$475,613Aaron F Straight · Stanford University · R01 · FY2024 · CA
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
$475,286Barbara Burtness · Yale University · P50 · FY2024 · DE
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
$475,275Marcus E Peter · Northwestern University At Chicago · R01 · FY2022 · CA
Role of T Regulatory Cell Suppression in Autoimmunity and Cancer
$475,184Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$474,931Lajos Pusztai · Yale University · R01 · FY2020 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$474,721Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2022 · CA